Moodys Investors Service - GlaxoSmithKline plc (GSK) For GSK, Delay of Generic Advair Is Credit Positive

Report

Moody's Investors Service

EUR 185.42 For Business Accounts Only

For GSK, Delay of Generic Advair Is Credit Positive

Â Â ISSUERÂ COMMENTÂ CORPORATESÂ Â MAYÂ 15,Â 2017Â Â ForÂ GSK,Â DelayÂ ofÂ GenericÂ AdvairÂ IsÂ Â CreditÂ PositiveÂ FromÂ CreditÂ Outlook Â On Thursday,Â theÂ USÂ FoodÂ andÂ DrugÂ AdministrationÂ (FDA)Â issued aÂ completeÂ responseÂ letterÂ (CRL) t

15/05/2017 3 EN

Underlying

GlaxoSmithKline plc

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.

See profile

GB0009252882 London Stock Exchange United Kingdom

Provider

Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations

Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.

Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.

See profile

Other Reports on these Companies

SmartInsider

GSK: 1 director

A director at GSK bought 3,334 shares at 2,219p and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members alon...

Free Trial

February 21, 2026 February 21, 2026 1 EN

New Street Research

GSK - Cut to Sell - Recent Surge Unjustified (SELL [HOLD], TP £19 [18], 17pgs)

For access to the full note, please contact Naresh Chouhan ( )

EUR 4233.00

February 12, 2026 February 12, 2026 1 EN

Hardman & Co

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025. While this sounds positive, it was below the strong performance of most major UK healthcare stocks and, in general, it underperformed its UK and peer benchmarks: FTSE 100 (+21.5%); FTSE All-Share (+19.8%); and the NASDAQ Biotech Index (NBI; +32.4%). The HHI outperformed only the FTSE AIM All-Share Index (+6.5%). 19 (39%) companies in our index saw sh...

January 14, 2026 January 14, 2026 1 EN

Multilateral Development Banks and Other Supranational Entities: Proposed Methodology Update

This Request for Comment describes proposed updates to our Multilateral Development Banks and Other Supranational Entities methodology.

26m 26m 1 EN

Non-performing and Re-performing Loan Securitizations: Proposed Methodology Update

This Request for Comment describes proposed updates to our “Non-performing and Re-performing Loan Securitizations” methodology.

26m 26m 1 EN

POSCO: Update following change in outlook to negative from stable

Our credit view of this issuer reflects its sound credit quality of POSCO Holdings, offset by its significant capital spending in 2026.

41m 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN